ArticleResearch (Washington, D.C.)2026
IFI44 Promotes Clear Cell Renal Cell Carcinoma Progression via PRDX1 and Predicts Poor Prognosis.
Article in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell renal cell carcinoma (ccRCC) is a lethal urologic malignancy with limited biomarkers for prognosis and therapeutic stratification. Interferon-induced protein 44 (IFI44) has been implicated in immune regulation, but its role in ccRCC is unclear. To address this gap, we comprehensively investigated the clinical significance, biological roles, and molecular mechanisms of IFI44 in ccRCC pathogenesis. Using integrative transcriptomic analysis of the Gene Expression Omnibus and the Cancer Genome Atlas-Kidney Clear Cell Carcinoma cohorts, we first identified IFI44 as a key candidate gene. Bioinformatic enrichment analyses and immune infiltration profiling were conducted to investigate potential mechanisms. In parallel, we established ccRCC cell lines with stable IFI44 knockdown and evaluated phenotypic changes using Cell Counting Kit-8, Transwell assays, wound-healing assays, and flow cytometry, thereby examining cell proliferation, apoptosis, migration, and invasion. We observed that IFI44 was markedly elevated in ccRCC tissues, and its increased level was closely associated with advanced tumor stage and poorer patient survival. Enrichment analyses indicated that IFI44 participates in pathways related to viral response, RNA splicing, and mRNA processing. Moreover, elevated IFI44 expression may be associated with an immunosuppressive tumor microenvironment, as suggested by increased infiltration of effector T cells and M1 macrophages, along with decreased infiltration of activated dendritic cells. In mechanistic studies, IFI44 knockdown markedly suppressed cell proliferation, triggered apoptosis, and reduced both migratory and invasive capacities, whereas PRDX1 overexpression rescued these phenotypes and PRDX1 was shown to interact with IFI44. In summary, the data show that IFI44 acts as an oncogene in ccRCC, promoting tumor progression through its interaction with PRDX1 while also shaping an immunosuppressive microenvironment, and suggest that IFI44 is a promising biomarker of prognosis and candidate therapeutic target for ccRCC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.